|
1）Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012; 30: 820-9
|
|
|
|
2）Greenberg PL, Tüechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120: 2454-65
|
|
|
|
|
|
3）Vosa MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian region database. J Clin Oncol. 2013; 31: 2671-7
|
|
|
|
|
|
4）National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myelodysplastic Syndromes version 2. 2014
|
|
|
|
|
|
5）Sperr WR, Wimazal K, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010; 21: 114-9
|
|
|
|
|
|
6）Wang R, Gross CP, Halene S, et al. Comorbidity and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res. 2009; 33: 1594-8
|
|
|
|
|
|
7）Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: An International collaborative decision analysis. J Clin Oncol. 2013; 31: 2671-7
|
|
|
|
|
|
8）Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneousor intravenous administration of romiplostim in thrombocytopenic patients with low risk myelodysplastic syndromes. Cancer. 2011; 117: 992-1000
|
|
|
|
|
|
9）Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with low risk myelodysplastic syndrome. Leuk Res. 2011; 35: 323-8
|
|
|
|
|
|
10）Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product a (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113: 6541-8
|
|
|
|
|
|
11）Garcia-Manero G, Gore SD, Cogle C, et al. Phase 1 study of oral azacitidine in myelodysplastic syndromes. Chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011; 29: 2521-7
|
|
|
|
|
|
12）Faderi S, Garcia-Manero G , Estrov Z, et al. Oral clofarabine in the treatment of patients with high-risk myelodysplastic syndrome. J Clin Oncol. 2010; 28: 2755-60
|
|
|
|
|
|
13）Faderi S, Garcia-Manero G, Ravandi F, et al. A randomized study of low dose oral clofarabine 10 mg versus 20 mg (flat dose) daily × 5 for patients with higher-risk myelodysplastic syndrome (MDS). 54th ASH Annual meeting and exposition. (abstract 3851), 2012
|
|
|
|
|
|
14）Gumireddy K, Reddy MV, Cosenza SC, et al. ONO1910, a non-ATP-competitive small molecule inhibitor of PLK 1, is a potent anticancer agent. Cancer Cell. 2005; 7: 275-86
|
|
|
|
|